H1N1ワクチンの世界市場レポート 2025年

H1N1ワクチンの市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.8%で47億9,000万米ドルに成長します。予測期間の成長は、広域スペクトルワクチンの調査、世界のワクチン公平性イニシアティブ、公衆衛生レジリエンス構築、世界ヘルスガバナンス強化、h1n1ワクチン接種と定期予防接種の統合などに起因しています。予測期間における世界の動向には、世界的流行への備え、インフルエンザワクチン接種プログラム、ワクチン開発の進展、交差防御研究、世界ヘルスイニシアチブ、ワクチン製造における技術改善、生産能力拡大、データモニタリングとサーベイランスなどが含まれます。

免疫学とワクチンに関連する研究開発活動への投資の増加は、今後のH1N1ワクチン市場の成長を促進すると予想されます。免疫学とワクチンは、感染症を予防し、感染症と闘うための抗体産生を促進する上で不可欠な役割を担っています。この分野は、免疫システムをより深く理解しようとする医学・生物学研究に欠かせないです。H1N1ワクチンは、特に抗体産生を促進し、様々な病気に対する免疫力を提供するように設計されています。例えば、2023年3月、米国を拠点とする国立衛生研究所（NIH）は、その研究によりmRNA COVID-19ワクチンの迅速な開発が促進されたと報告しました。2022年3月までに、米国では5億7,700万回以上の接種が行われ、推定240万人の命が救われ、1,700万人の入院が予防されました。そのため、免疫学とワクチンの研究開発への支出の増加は、H1N1ワクチン市場の拡大に大きく寄与しています。

海外旅行の急増は、H1N1ワクチン市場の起爆剤となっています。観光やビジネスなど、国境を越えた移動を伴う海外旅行では、予防措置としてH1N1ワクチン接種が求められます。国や国際機関は、旅行中のウイルス・トランスミッションを抑制するため、H1N1ワクチン接種を推奨または義務付けています。国際観光収入は2022年に1兆ドルに達し、パンデミック前の64％に達します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のH1N1ワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のH1N1ワクチン市場：成長率分析
• 世界のH1N1ワクチン市場の実績：規模と成長, 2019-2024
• 世界のH1N1ワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界のH1N1ワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のH1N1ワクチン市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不活化ワクチン
• 生弱毒化ワクチン
• 世界のH1N1ワクチン市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 皮内ワクチン接種
• 筋肉内ワクチン接種
• 皮下ワクチン接種
• 世界のH1N1ワクチン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 研究および診断ラボ
• その他のエンドユーザー
• 世界のH1N1ワクチン市場：不活化ワクチンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射用不活化ワクチン
• 鼻腔内不活化ワクチン
• 世界のH1N1ワクチン市場：生弱毒化ワクチンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射用生弱毒化ワクチン
• 鼻腔内生弱毒化ワクチン

第7章 地域別・国別分析

• 世界のH1N1ワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のH1N1ワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• H1N1ワクチン市場：競合情勢
• H1N1ワクチン市場：企業プロファイル
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • CSL Limited Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Zydus Lifesciences Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck and Co.Inc.
• Novavax Inc.
• Panacea Biotec Ltd.
• Sinovac Biotech Ltd.
• Green Cross Corp.
• Pfizer Inc.
• Seqirus Ltd.
• Cipla Inc.
• Protein Sciences Corporation
• Hualan Biological Engineering Inc.
• Changsheng Bio-Technology Co. Ltd.
• Bharat Biotech International Limited
• Serum Institute of India Pvt. Ltd.
• Bio Farma Group
• PT Kalbe Farma Tbk

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• H1N1ワクチン市場2029：新たな機会を提供する国
• H1N1ワクチン市場2029：新たな機会を提供するセグメント
• H1N1ワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

H1N1 vaccines are designed for individuals aged six months and older to guard against influenza triggered by the H1N1 2009 virus. These vaccines work by introducing a small, weakened dose of the virus into the body, stimulating the immune system to build protection against the virus.

The primary product types for H1N1 vaccines include inactivated and live attenuated vaccines. Inactivated vaccines within the market are formulated to prevent diseases caused by the influenza H1N1 virus. They consist of synthetic vaccines with protective immunizing properties, containing hemagglutinin (HA) antigens derived from four inactivated influenza viruses, encompassing two distinct influenza type A strains and two different influenza type B strains. These vaccines are administered through various routes such as intradermal, intramuscular, and subcutaneous methods, and they are utilized across hospitals, clinics, research and diagnostic laboratories, among other medical settings.

The H1N1 vaccine market report is one of a series of new reports from The Business Research Company that provides H1N1 vaccine market statistics, including H1N1 vaccine industry global market size, regional shares, competitors with an H1N1 vaccine market share, detailed H1N1 vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the H1N1 vaccine industry. This H1N1 vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The H1N1 vaccine market size has grown strongly in recent years. It will grow from $3.33 billion in 2024 to $3.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to previous influenza outbreaks, global health security concerns, vaccine development and approval processes, global vaccination campaigns, public health education initiatives, government funding and subsidies, pharmaceutical industry agility.

The H1N1 vaccine market size is expected to see strong growth in the next few years. It will grow to $4.79 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to research on broad-spectrum vaccines, global vaccine equity initiatives, public health resilience building, global health governance strengthening, integration of h1n1 vaccination with routine immunization. Major trends in the forecast period include global pandemic preparedness, influenza vaccination programs, vaccine development advances, cross-protection research, global health initiatives, technological improvements in vaccine manufacturing, production capacity expansion, data monitoring and surveillance.

The rising investment in research and development activities related to immunology and vaccines is expected to drive the growth of the H1N1 vaccine market in the future. Immunology and vaccines play essential roles in preventing infections and promoting the production of antibodies to combat them. This field is vital in medical and biological research, as it seeks to understand the immune system better. The H1N1 vaccine is specifically designed to enhance antibody production, providing immunity against various diseases. For instance, in March 2023, the National Institutes of Health (NIH), a U.S.-based agency, reported that its research had facilitated the rapid development of mRNA COVID-19 vaccines. By March 2022, over 577 million doses had been administered in the United States, saving an estimated 2.4 million lives and preventing 17 million hospitalizations. Therefore, the growing expenditure on research and development in immunology and vaccines is significantly contributing to the expansion of the H1N1 vaccine market.

The surge in international travel is a catalyst for the H1N1 vaccine market. International travel, involving cross-border movement for tourism, business, and more, demands H1N1 vaccination as a preventive measure. Nations and global bodies recommend or mandate H1N1 vaccination to curb virus transmission during travel. International tourism receipts hitting $1 trillion in 2022 and reaching 64% of pre-pandemic levels signify the market's growth fueled by increased travel safety measures.

Strategic collaborations among companies are emerging as a significant trend in the H1N1 (swine flu) vaccination market. Firms in this sector are increasingly focusing on partnerships to enhance their market share. For instance, in August 2022, a prominent pharmaceutical company and hVIVO, an affiliate of Open Orphan, entered into a $123 million agreement to develop a new batch of H1N1 influenza challenge virus. This collaboration has bolstered the growth potential for both companies within the industry.

Innovations like needle-free nasal vaccines propel the H1N1 vaccine market. Needle-free nasal vaccines, devoid of traditional needles or syringes, offer a painless, non-invasive immunization method, predominantly through nasal administration. Nasovac S4, launched by Serum Institute and Mylab in October 2023, targets H1N1 and H3N2 viruses, stimulating immune response in individuals aged 2 and above against influenza strains A and B, underscoring market sustainability and product advancements.

In July 2023, Sinovac Biotech Ltd., a prominent biopharmaceutical company based in China, forged a strategic partnership with Bio Farma, a state-owned biopharmaceutical company based in Indonesia, for an undisclosed investment. This alliance is designed to cater to Indonesia's domestic vaccine market while targeting expansion into the international sphere. The collaboration between Sinovac and Bio Farma is aimed at facilitating Sinovac's introduction of upcoming products, such as varicella, influenza, and pneumococcal polysaccharide vaccines. These initiatives are intended to address the healthcare needs of the region effectively and contribute to the enhancement of local and national public health initiatives. Bio Farma is an Indonesia-based state-owned biopharmaceutical company, operating in various vaccine markets, including H1N1.

Major companies operating in the H1N1 vaccine market are Sanofi SA, GlaxoSmithKline PLC, CSL Limited, AstraZeneca Inc., Zydus Lifesciences Limited, Merck and Co.Inc., Novavax Inc., Panacea Biotec Ltd., Sinovac Biotech Ltd., Green Cross Corp., Pfizer Inc., Seqirus Ltd., Cipla Inc., Protein Sciences Corporation, Hualan Biological Engineering Inc., Changsheng Bio-Technology Co. Ltd., Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Bio Farma Group, PT Kalbe Farma Tbk, Moderna Inc., CureVac NV, BioNTech SE, Inovio Pharmaceuticals Inc., Vaxart Inc., Altimmune Inc., Dynavax Technologies Corporation, VBI Vaccines Inc., GeoVax Labs Inc.

North America was the largest region in the H1N1 vaccine market in 2024. The regions covered in the h1n1 vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the h1n1 vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The H1N1 vaccines market consists of sales of TIV (flu shot (injection) and LAIV (nasal spray (mist) of live attenuated influenza vaccine). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

H1N1 Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on h1n1 vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for h1n1 vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The h1n1 vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Inactivated Vaccine; Live Attenuated Vaccine
• 2) By Route Of Administration: Intradermal Vaccination; Intramuscular Vaccination; Subcutaneous Vaccination
• 3) By End Users: Hospitals; Clinics; Research And Diagnostic Laboratories; Other End Users
• Subsegments:
• 1) By Inactivated Vaccine: Injectable Inactivated Vaccine; Intranasal Inactivated Vaccine
• 2) By Live Attenuated Vaccine: Injectable Live Attenuated Vaccine; Intranasal Live Attenuated Vaccine
• Companies Mentioned: Sanofi SA; GlaxoSmithKline PLC; CSL Limited; AstraZeneca Inc.; Zydus Lifesciences Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. H1N1 Vaccine Market Characteristics

3. H1N1 Vaccine Market Trends And Strategies

4. H1N1 Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global H1N1 Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global H1N1 Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global H1N1 Vaccine Market Growth Rate Analysis
• 5.4. Global H1N1 Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global H1N1 Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global H1N1 Vaccine Total Addressable Market (TAM)

6. H1N1 Vaccine Market Segmentation

• 6.1. Global H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Vaccine
• Live Attenuated Vaccine
• 6.2. Global H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intradermal Vaccination
• Intramuscular Vaccination
• Subcutaneous Vaccination
• 6.3. Global H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Research and Diagnostic Laboratories
• Other End Users
• 6.4. Global H1N1 Vaccine Market, Sub-Segmentation Of Inactivated Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Inactivated Vaccine
• Intranasal Inactivated Vaccine
• 6.5. Global H1N1 Vaccine Market, Sub-Segmentation Of Live Attenuated Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Live Attenuated Vaccine
• Intranasal Live Attenuated Vaccine

7. H1N1 Vaccine Market Regional And Country Analysis

• 7.1. Global H1N1 Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global H1N1 Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific H1N1 Vaccine Market

• 8.1. Asia-Pacific H1N1 Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China H1N1 Vaccine Market

• 9.1. China H1N1 Vaccine Market Overview
• 9.2. China H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India H1N1 Vaccine Market

• 10.1. India H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan H1N1 Vaccine Market

• 11.1. Japan H1N1 Vaccine Market Overview
• 11.2. Japan H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia H1N1 Vaccine Market

• 12.1. Australia H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia H1N1 Vaccine Market

• 13.1. Indonesia H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea H1N1 Vaccine Market

• 14.1. South Korea H1N1 Vaccine Market Overview
• 14.2. South Korea H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe H1N1 Vaccine Market

• 15.1. Western Europe H1N1 Vaccine Market Overview
• 15.2. Western Europe H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK H1N1 Vaccine Market

• 16.1. UK H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany H1N1 Vaccine Market

• 17.1. Germany H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France H1N1 Vaccine Market

• 18.1. France H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy H1N1 Vaccine Market

• 19.1. Italy H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain H1N1 Vaccine Market

• 20.1. Spain H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe H1N1 Vaccine Market

• 21.1. Eastern Europe H1N1 Vaccine Market Overview
• 21.2. Eastern Europe H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia H1N1 Vaccine Market

• 22.1. Russia H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America H1N1 Vaccine Market

• 23.1. North America H1N1 Vaccine Market Overview
• 23.2. North America H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA H1N1 Vaccine Market

• 24.1. USA H1N1 Vaccine Market Overview
• 24.2. USA H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada H1N1 Vaccine Market

• 25.1. Canada H1N1 Vaccine Market Overview
• 25.2. Canada H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America H1N1 Vaccine Market

• 26.1. South America H1N1 Vaccine Market Overview
• 26.2. South America H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil H1N1 Vaccine Market

• 27.1. Brazil H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East H1N1 Vaccine Market

• 28.1. Middle East H1N1 Vaccine Market Overview
• 28.2. Middle East H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa H1N1 Vaccine Market

• 29.1. Africa H1N1 Vaccine Market Overview
• 29.2. Africa H1N1 Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa H1N1 Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa H1N1 Vaccine Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. H1N1 Vaccine Market Competitive Landscape And Company Profiles

• 30.1. H1N1 Vaccine Market Competitive Landscape
• 30.2. H1N1 Vaccine Market Company Profiles
  • 30.2.1. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. CSL Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Zydus Lifesciences Limited Overview, Products and Services, Strategy and Financial Analysis

31. H1N1 Vaccine Market Other Major And Innovative Companies

• 31.1. Merck and Co.Inc.
• 31.2. Novavax Inc.
• 31.3. Panacea Biotec Ltd.
• 31.4. Sinovac Biotech Ltd.
• 31.5. Green Cross Corp.
• 31.6. Pfizer Inc.
• 31.7. Seqirus Ltd.
• 31.8. Cipla Inc.
• 31.9. Protein Sciences Corporation
• 31.10. Hualan Biological Engineering Inc.
• 31.11. Changsheng Bio-Technology Co. Ltd.
• 31.12. Bharat Biotech International Limited
• 31.13. Serum Institute of India Pvt. Ltd.
• 31.14. Bio Farma Group
• 31.15. PT Kalbe Farma Tbk

32. Global H1N1 Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The H1N1 Vaccine Market

34. Recent Developments In The H1N1 Vaccine Market

35. H1N1 Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 H1N1 Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 H1N1 Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 H1N1 Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer